You searched for Parkinson's - Page 14 of 20

Best in Biotech 25 Mar 2025

These 7 biotechs are shaping the next generation of endometriosis care

…company Kissei Pharmaceutical has drug candidates in its pipeline to address different kinds of diseases, including Parkinson’s disease and non-muscle-invasive bladder cancer. But the biotech company’s most advanced drug in…

March 25, 2025 - 9 minutesmins - By Roohi Mariam Peter

News and Trends 2 Jan 2025

A surge in deals: GSK bets on ADC, neuro and fibrotic diseases to bolster drug development

…small molecule candidate to treat people with Parkinson’s disease. Vesalius was founded by the life sciences venture capital Flagship Pioneering. The startup incubator and GSK pooled in $150 million in…

January 2, 2025 - 6 minutesmins - By Roohi Mariam Peter

News and Trends 1 Oct 2018

Update: Forbion’s Life Science Fund Tops Goal by €90M

…in its portfolio, working in Parkinson’s, was acquired by Lundbeck in a deal that could reach near €1Bn. Other successes have been the €464M acquisition of Rigontec and a smaller…

October 1, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 May 2017

Danish Biotech Targeting Ion Channels Completes Private Placement

…wide range of conditions, such as obesity, type 2 diabetes, cocaine addiction, Parkinson’s, and schizophrenia, the latter being researched in collaboration with Boehringer Ingelheim. Cover image via TJmedia /Shutterstock …

May 17, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Best in Biotech 22 Jan 2025

Curing ALS? Sixteen companies developing new treatments in 2025

…as C9orf72 in ALS and frontotemporal dementia. As of now, its ALS treatment is in the discovery phase, along with two other programs focused on Parkinson’s and Alzheimer’s. As its…

January 22, 2025 - 18 minutesmins - By Jules Adam

Best in Biotech 28 Jul 2022

Five companies personalizing treatments with 3D printed drugs

…3D printing of ropinirole tablets for Parkinson’s disease. 3D inkjet printing deposits liquid materials or solid suspensions layer-by-layer but each deposited layer must first be dried, or “cured,” between the…

July 28, 2022 - 5 minutesmins - By Omnia Ibrahim

Best in Biotech 15 Mar 2023

10 immunotherapy companies making waves in 2023

…diseases like Parkinson’s. ElevateBio is looking to develop iPSC-derived therapies, for which it set up a new company in 2022, in a collaborative effort with Boston Children’s Hospital, where it…

March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 8 May 2020

Phase III Failure Sinks Drug for Rare Neurological Disorder

…licensed from Merck KGaA after it failed phase III trials for Parkinson’s disease — had been billed as the first therapy to become independently commercialized by Newron. Adding to the…

May 8, 2020 - 4 minutesmins - By Anita Chakraverty

News and Trends 13 Sep 2022

WhiteLab Genomics raises $10M for AI-powered genomic therapies platform

…4,000 human diseases including Alzheimer’s disease, Parkinson’s disease, cystic fibrosis, cardiovascular disease, Duchenne muscular dystrophy, and some types of cancer, originate from errors and changes in an individual’s DNA sequence….

September 13, 2022 - 3 minutesmins - By Jim Cornall

Best in Biotech 28 Jan 2020

10 Scientists Behind Modern Biotech You Probably Don’t Know

…treatments for sickle-cell anemia and Parkinson’s disease using these cells. Françoise Barré-Sinoussi (born 1947) Francois Barre-Sinoussi, 2012 – International AIDS Conference in Washington DC. Photo credit: Michael Fleshman Françoise Barré-Sinoussi…

January 28, 2020 - 8 minutesmins - By Helen Albert

News and Trends 11 Jan 2023

We DUB this target ‘druggable’

…cellular health and longevity. Recently presented at the 2022 Society for Neuroscience (SfN) conference, new data from the Beth Israel Deaconess Medical Center (BIDMC) cements Parkinson’s disease (PD) as a…

January 11, 2023 - 5 minutesmins - By External Contributor

Best in Biotech 2 Apr 2024

Chicago biotech: Seven players advancing the industry

…diseases. Their lead program is VQ-101, a small molecule designed to activate glucocerebrosidase (GCase), particularly targeting Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB), a type of progressive dementia…

April 2, 2024 - 8 minutesmins - By Jules Adam

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Parkinson's

These 7 biotechs are shaping the next generation of endometriosis care

A surge in deals: GSK bets on ADC, neuro and fibrotic diseases to bolster drug development

Update: Forbion’s Life Science Fund Tops Goal by €90M

Danish Biotech Targeting Ion Channels Completes Private Placement

Curing ALS? Sixteen companies developing new treatments in 2025

Five companies personalizing treatments with 3D printed drugs

10 immunotherapy companies making waves in 2023

Phase III Failure Sinks Drug for Rare Neurological Disorder

WhiteLab Genomics raises $10M for AI-powered genomic therapies platform

10 Scientists Behind Modern Biotech You Probably Don’t Know

We DUB this target ‘druggable’

Chicago biotech: Seven players advancing the industry

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!